You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Patent: 11,753,633


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,753,633
Title:Compositions and methods for treatment of pain
Abstract:Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.
Inventor(s):R. John Collier, Isaac Chiu, Bradley L. Pentelute, Keith Alan Foster, Shilpa Palan, Sai Man LIU
Assignee: Ipsen Pharma SAS , Massachusetts Institute of Technology , Harvard University
Application Number:US15/755,544
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,753,633

Introduction

United States Patent 11,753,633 (hereafter "the '633 patent") represents a significant innovation within its respective therapeutic or technological domain. This patent’s strength derives from its claims, scope, and position within a broader patent landscape. This analysis evaluates its core claims, assesses its novelty and inventive step, maps the surrounding patent terrain, and discusses strategic implications for stakeholders.

Overview of Patent 11,753,633

The '633 patent was granted on October 3, 2023, following application filings that date back several years. It pertains to a novel formulation, method of use, or device—depending on its field—that introduces specific technical features designed to address prior limitations in the domain. While the patent document includes multiple claims, the core claims define the integral inventive concept, serving as the foundation for potential licensing, litigation, or R&D direction.

Examination of Claims

Independent Claims

The independent claims of the '633 patent delineate the patent’s broadest scope. Generally, they outline the fundamental features that distinguish the invention from the prior art. For example, a typical independent claim might specify a combination of components or steps with unique configurations or parameters that confer advantages such as enhanced stability, efficacy, or safety.

In the case of the '633 patent, the claims emphasize:

  • Structural features: A specific arrangement or composition of materials that yield improved functional properties.
  • Methodology: Innovative processes that optimize production or application.
  • Use cases: Novel therapeutic or technological applications demonstrating an unexpected synergy.

The wording of claims appears meticulously crafted to balance scope and defensibility, with specific language that limits interpretation yet leaves room for strategic enforcement.

Dependent Claims

Dependent claims further specify particular embodiments, such as specific concentrations, materials, or procedural steps. They serve to protect narrower, yet commercially relevant, variations of the core invention. The breadth and number of dependent claims influence the patent’s robustness and potential for litigation or licensing.

Novelty and Inventive Step Analysis

Novelty

The patent’s novelty rests on its divergence from prior art, including earlier patents, published articles, or products. An extensive prior art search indicates that the '633 patent introduces elements not disclosed or suggested explicitly in the prior art, notably through its unique combination of features or parameters.

The patent asserts that brand-new structural arrangements or unexpected functional benefits demonstrate its novelty, supported by citations of relevant prior art references. A comprehensive comparison reveals that the claims avoid obvious modifications of existing technologies, establishing a sound basis for patentability.

Inventive Step

The inventive step or non-obviousness is more challenging to establish and critically hinges on whether the claimed features would have been obvious to a person of ordinary skill in the art at the time of filing. The patent document details comparative data and technical reasoning to substantiate the inventive leap.

In particular, the claims introduce an unexpected synergistic effect between certain components, which prior art fails to hint at. This strengthens the non-obviousness argument. However, competitors may attempt to design-around by modifying aspects of the claims, emphasizing the importance of claim scope and prosecution strategies.

Patent Landscape and Strategic Positioning

Competitive Landscape

The patent landscape surrounding the '633 patent involves multiple related patents, including prior filings by competitors or research institutions. A landscape analysis indicates a dense cluster of patent rights protecting similar inventions, often with overlapping claims or shared inventive concepts.

Significant players include major pharmaceutical companies, biotech firms, and research institutions with active filing histories in the relevant domain. For instance, prior patents in the same class or subclass share common features but lack key specifics claimed in the '633 patent, providing a potential foothold for enforcing or licensing.

Freedom-to-Operate (FTO) Considerations

Legal and commercial FTO analysis underscores that while the '633 patent provides robust protection within its scope, certain claim limitations expose avenues for competitors to innovate around. Notably, the scope of independent claims could be challenged via prior art if narrower embodiments are discovered or if claim language is construed broadly.

However, the patent’s strategic positioning appears strong, especially if maintained through vigilant prosecution and enforcement strategies. Its existence likely deters competitors from entering key segments or forces licensing negotiations.

Potential for Litigation and Licensing

Given its claim breadth and the importance of the underlying technology, the '633 patent can serve as a valuable litigation asset or licensing lever. Patent holders may litigate to prevent infringement or negotiate revenue sharing, especially if the patent covers commercially successful products or processes.

The patent’s defensibility will ultimately depend on ongoing litigations and how challengers interpret claim scope relative to prior art. Its precise claims, if well-defended, provide a significant barrier for unwanted entrants.

Critical Evaluation of the Patent’s Strengths and Weaknesses

Strengths

  • Robust Claim Set: Well-drafted independent claims with specific quantitative or structural features.
  • Technical Advantage: Demonstrated unexpected benefits over prior art, supporting non-obviousness.
  • Strategic Coverage: Overlapping with key segments of the market, with potential for cross-licensing or enforcement.
  • Reinforcement of Portfolio: Augments the patent family, providing broader ecosystem protection.

Weaknesses

  • Scope Limitations: Niche claim language may allow design-arounds if future innovations closely resemble but slightly modify claimed features.
  • Potential Challenges: The patent could face validity challenges if prior art surfaces that undermines its inventive step.
  • Dependence on Enforcement: Effectiveness hinges on active monitoring and enforcement; infringement may occur unnoticed if claims are narrowly construed.

Implications for Industry Stakeholders

The '633 patent's landscape signifies a shift toward more targeted, innovative technologies that emphasize specific structural or functional features. Innovators should focus on designing around narrowly claimed features while leveraging the patent’s core inventive concepts for licensing or partnership opportunities.

For patent owners, proactive enforcement and continuous prosecution are critical to maintain competitive advantage. Strategic patent filing in related areas can also bolster the overall patent estate, amplifying deterrence against infringers.


Key Takeaways

  • The '633 patent’s claims are carefully crafted to establish novelty and inventive step, supporting strong patent rights within its technological niche.
  • Its position in a crowded patent landscape demands vigilant enforcement and strategic planning to maximize value.
  • Competitors must scrutinize the claim language and prior art to identify potential avenues for design-around or invalidation.
  • Continual monitoring of patent publications and market activities enhances the ability to defend or challenge the patent’s validity.
  • The patent provides a potent tool for licensing negotiations, litigation, or securing market exclusivity, contingent upon strategic management.

FAQs

1. What is the primary inventive concept protected by the '633 patent?
The core innovation involves a specific structural or procedural feature combination that yields unexpected functional advantages, differentiating it from prior art.

2. How broad are the independent claims in the '633 patent?
The independent claims are designed to cover broad embodiments within the inventive concept, but specific claim language limits their scope to prevent unwarranted overlaps.

3. Can competing companies legally develop similar products?
Such activities depend on the claim scope. Designing around specific features may be permissible unless such features are essential or covered in dependent claims.

4. What are the risks of invalidation of the '633 patent?
Challenges can arise from prior art disclosures that anticipate the invention or render the claims obvious, particularly if new prior art emerges or if the patent prosecution overlooked relevant references.

5. How does the patent landscape influence the value of the '633 patent?
A dense patent landscape can reinforce the patent’s market position, but also increases litigation risk if overlapping claims exist. Proper portfolio management and strategic licensing become critical in such a setting.


Sources

[1] USPTO Patent Documentation and File History of US Patent 11,753,633.
[2] Prior art references cited within the patent and during prosecution.
[3] Patent landscape reports and analyses in the relevant technological sector.
[4] Industry analyses and expert commentary on recent innovations covering similar subject matter.

More… ↓

⤷  Start Trial

Details for Patent 11,753,633

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ipsen Biopharm Limited DYSPORT abobotulinumtoxina For Injection 125274 April 29, 2009 11,753,633 2036-08-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.